PIK3CA and cervical cancer: Consistent with results from scratch assays, cervical cancer cells carrying the PIK3CA-E545K mutation (HeLa-E545K, Figure 7C, and CaSki, Figure 7D), displayed enhanced migration compared to cells expressing wild type PIK3CA. Moreover, as in scratch assays, treatment with GDC-0941 (in combination with radiation and cisplatin) reduced cell migration in CaSki and HeLa-E545K cells (Figure 7).